Skip to content
TrialMatch
Sign up
Recruiting

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.

Condition
Metastatic NSCLC - Non-Small Cell Lung Cancer
Sponsor
Necmettin Erbakan University

Who can join

Age
18 to 90 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 6

  • Minimum age: 18 years
  • Maximum age: 90 years
  • Study condition: Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Histological and staging diagnosis of metastatic non-small cell lung cancer
  • ECOG performance score between 0 and 2
  • No contraindications for nivolumab

Exclusion 7

  • Patients diagnosed with mNSCLC who received nivolumab as adjuvant or perioperative therapy
  • Those with a second primary malignancy undergoing active treatment
  • Those who have not signed the informed consent form
  • Those with additional hematological malignancies such as leukemia, lymphoma, or myelodysplastic syndrome
  • Those who have undergone palliative or curative radiotherapy within the last three months
  • Those with active viral/bacterial infections before nivolumab treatment
  • Patients who have used steroids in the last three months

Where

1 site, 1 recruiting

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology

Konya, Meram, Turkey (Türkiye)

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.